FDA approves menopause treatment from Pfizer, Ligand


The FDA approves Pfizer's (PFE) Duavee for the treatment of moderate-to-severe hot flashes and for the prevention of post-menopausal osteoporosis.

PFE partner Ligand Pharmaceuticals (LGND) got a big boost from the news Thursday, rising 7%.

Notably, the drug is a selective estrogen receptor modulator combined with conjugated estrogens. Premarin is a conjugated estrogen tablet and made the news earlier this week after new research suggested there may be a link between the drug and the risk of blood clots.

Another FDA-approved post-menopausal osteoporosis drug is Eli Lilly's (LLY) Evista.

From other sites
Comments (3)
  • 12100131
    , contributor
    Comments (20) | Send Message
     
    Congrats to all longs! Ligand is on a roll. The Beacon VP analysts and irina and her crew at Cantor will have to reassess Ligand. A recent article in Forbes suggested that Ligand is one of the most shorted stock on NASDAQ. The squeeze is coming- hang on to those shares.
    4 Oct 2013, 09:11 AM Reply Like
  • bberuch
    , contributor
    Comments (314) | Send Message
     
    company has come a long way, It looks to have a fine future.
    Ligand is and has been adding to joint venture revenues on a growing number of drugs attacking nasty diseases and doing so with powerful partners.
    I have been a holder for 6 years, and foresee considerable additional growth. .
    4 Oct 2013, 10:57 AM Reply Like
  • churn
    , contributor
    Comments (206) | Send Message
     
    Hey what about my pfizer? Dont we a kicker out of this?
    4 Oct 2013, 11:27 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs